Corporate News

Grant of Options

08 March 2021

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that the Group's Remuneration Committee and the Board has, on 5 March 2021, approved the grant of 200,000 Options over ordinary shares of 4 pence each in the Company to Simon Douglas, Non-Executive Chairman, under the Company’s Third Unapproved Option Scheme.

The Options were granted with an exercise price of 89 pence each, being the closing middle market price on 4 March 2021. The Options will vest over three years, one third vesting on each anniversary of the grant date. Following the grant, these Options represent Simon Douglas’ only interest in the Company.


The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.


Omega Diagnostics Group PLCTel: 01259 763 030
Bill Rhodes, Interim Non-Executive Chairman  
Colin King, Chief Executive
Kieron Harbinson, Group Finance Director  
finnCap LtdTel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane (ECM)  
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1  Details of the person discharging managerial responsibilities/person closely associated
a. Name Simon Douglas
2  Reason for notification
a. Position/Status Non-Executive Chairman
b. Initial notification/
Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Omega Diagnostics Group Plc
b. LEI 2138007U9P4BTZTYIR92
4  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument,
type of instrument
Identification Code
200,000 Options over Ordinary Shares of 4 pence each were granted with an exercise price of 89 pence each. The Options will vest over three years, one third vesting on each anniversary of the grant date.
b. Nature of the transaction Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares
c. Price(s) and volume(s)  
Price(s) Volume(s)
89p 200,000
d. Aggregated information
Aggregated Purchase
Aggregated Purchase Price
Aggregated Sale Volume
Aggregated Sale Price
As above.      
e. Date of the transaction 5 March 2021   
f. Place of the transaction London Stock Exchange   

Sign up for Investor Alerts